title: Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases.
abstract: About half of the patients with paraneoplastic diseases develop an immune response against neuronal antigens expressed by both the tumor and the nervous system. In 31 patients with anti-Hu antibodies and 19 patients with anti-Yo antibodies, we searched for the presence of additional non-neuronal auto-antibodies and further studied whether the presence of such auto-antibodies was correlated with a specific oncological or neurological presentation. Positive antinuclear antibodies (ANA) were found at a titer of 1:40 or above in 48% patients with anti-Hu antibodies, and in 37% patients with anti-Yo antibodies. Anti-cytoplasmic antibodies were also detected in 42% patients with anti-Yo antibodies. No specific correlation between the presence of non-neuronal auto-antibodies and clinical characteristics of the patients could be identified. In particular, neither the type of underlying cancer, the overall survival, the tumor response to treatment, nor the neurological presentation were related to the serological status.
authors.affiliation: INSERM U 495 and Fédération de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, Paris, France.
authors.forename: Lucinda
authors.initials: L
authors.lastname: Aguirre-Cruz
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Charuel
authors.forename: Antoine F
authors.initials: AF
authors.lastname: Carpentier
authors.forename: Baya
authors.initials: B
authors.lastname: Benyahia
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Lucile
authors.initials: L
authors.lastname: Musset
mesh_terms: D000368:Aged; D000974:Antibodies, Antinuclear / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology; D018288:Carcinoma, Small Cell / Q000276:immunology; D004268:DNA-Binding Proteins / Q000276:immunology*; D051959:ELAV Proteins; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D009419:Nerve Tissue Proteins / Q000276:immunology*; D009474:Neurons / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology; D020361:Paraneoplastic Syndromes, Nervous System / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology; D016601:RNA-Binding Proteins / Q000276:immunology*; D014571:Urologic Neoplasms / Q000276:immunology
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies; C095184:CDR2 protein, human; D004268:DNA-Binding Proteins; D051959:ELAV Proteins; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins
references.citation: J Neurooncol. 2003 May;62(3):349-51
references.pmid: 12777089
references.citation: Neurology. 2001 Aug 14;57(3):558-9
references.pmid: 11502940
references.citation: Clin Chem Lab Med. 2000 Feb;38(2):117-22
references.pmid: 10834398
references.citation: J Neurol. 1996 Jan;243(1):51-6
references.pmid: 8869387
references.citation: Int Arch Allergy Appl Immunol. 1984;74(1):63-6
references.pmid: 6608501
references.citation: Arthritis Rheum. 1997 Sep;40(9):1601-11
references.pmid: 9324014
references.citation: Clin Cancer Res. 1999 Jun;5(6):1393-400
references.pmid: 10389924